Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose.
about
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsEfficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozinEffect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal modelsWhy Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humansPharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.Canagliflozin: a novel treatment option for type 2 diabetes.Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trialSodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Novel Agents for the Treatment of Type 2 Diabetes.Regulation of the human Na+-dependent glucose cotransporter hSGLT2.Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusRenal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetesSuppressing hyperinsulinemia prevents obesity but causes rapid onset of diabetes in leptin-deficient Lep(ob/ob) mice.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.The renal effects of SGLT2 inhibitors and a mini-review of the literature.Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature.A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.Industrial natural product chemistry for drug discovery and development.SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease.Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management?
P2860
Q26782225-8BFBD52E-8E23-4FB4-BB42-D8F81AE6D0EDQ28072765-57D149D6-1180-4F2D-8BE5-7A49AE59C8C6Q28074843-E52BD841-ECB3-4F2F-A05D-50806950181DQ28250844-26188A5A-7F82-4D60-AA23-826681A7F3BDQ28732080-AE794070-FD24-4EC7-BE6E-2F8E8AF2EBA7Q33354192-379A7EF5-3AC3-4811-93B6-F4D156111E01Q33356608-1500A05B-C912-43F0-BAD9-02F1AFADCAF9Q34105064-F29D7B1F-AF4C-455D-BE08-C456E7FF6968Q34153496-E356F3E8-8AE0-4373-9B26-7048E8094E27Q34388544-39D31D48-1990-44E2-B526-2272D592B331Q34503601-A2C65572-5461-492D-B199-3F5C73B06FC0Q34804900-28DCC7E2-2583-4164-9E54-20D706361CCBQ35831426-95055B4A-C90F-45D6-9893-807353A8CBADQ35906490-3555F0B4-0FB8-4E3B-B9CF-0D61330BE3ACQ35910421-5F19FA61-23DF-4208-B438-C092A5F395F5Q36175724-54A14D6A-058C-40CE-A893-7673466DBA72Q36232787-F4888EB5-6A15-40E3-BA7D-05459EAAF0ADQ36345951-303943F1-0FD9-4DBA-9CED-6792EF7C306AQ36782790-49285B32-1B95-4858-BFAA-6651A43396F7Q36937697-0E323BBA-48FF-4F53-B4AF-E7BA1DDEB7E7Q37139427-B7BCD7D2-F7C2-4C4C-9181-C6FC3D9DF4DAQ37193454-09DDDF9E-9225-41C8-97B2-5B6D42C4AE8FQ37368770-4A98CC1C-8769-4C03-B02F-74581D868FC6Q37588847-2A1496BB-FBA8-42D9-929B-C304B3A4A293Q37632127-D9560EB0-FA69-4140-AD17-CCAE8ECB8518Q37810292-B32F1400-E09D-4FF2-B13A-3F351543AAA3Q37890777-0E6EABEC-6CFC-4FE9-8CCA-3ABF81523EEFQ37940036-912C2E4D-248E-4144-B93D-F3AD0D1852ACQ37981884-B63A88F9-0296-457B-B61B-34DB6A860E34Q38084363-26962A31-B877-4A90-B9F1-84C64D82E2AEQ38154186-F32D3A7D-6DFF-4E1A-BE5D-94D517A4C411Q38176145-6E80D721-7259-4581-A50F-6B1367390CE6Q38201162-81598EEF-BF38-4513-815B-F74209481A96Q38205581-920E32D6-2FC6-4738-BC43-C94947999F56Q38250445-18C5953B-7364-4359-8B9C-A6FF98FBD440Q38260349-D9EBE250-B972-4452-8CF7-BE2352F9B23AQ38270203-E956ADCD-3DEB-4D59-978D-6C04D9104DE5Q38330456-A03C3726-E4A7-4238-BCCD-2C33B300727EQ38715153-2FE2ACE2-2690-445E-AE69-3468AEC253FDQ38768667-64B1DCC4-D6B7-47B4-BD16-328372D7E825
P2860
Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose.
description
1951 nî lūn-bûn
@nan
1951 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1951 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1951年の論文
@ja
1951年学术文章
@wuu
1951年学术文章
@zh-cn
1951年学术文章
@zh-hans
1951年学术文章
@zh-my
1951年学术文章
@zh-sg
1951年學術文章
@yue
name
Effect of diabetes and insulin ...... l tubules to reabsorb glucose.
@ast
Effect of diabetes and insulin ...... l tubules to reabsorb glucose.
@en
type
label
Effect of diabetes and insulin ...... l tubules to reabsorb glucose.
@ast
Effect of diabetes and insulin ...... l tubules to reabsorb glucose.
@en
prefLabel
Effect of diabetes and insulin ...... l tubules to reabsorb glucose.
@ast
Effect of diabetes and insulin ...... l tubules to reabsorb glucose.
@en
P2093
P356
P1476
Effect of diabetes and insulin ...... l tubules to reabsorb glucose.
@en
P2093
P304
P356
10.1172/JCI102424
P407
P577
1951-02-01T00:00:00Z